@article{8b682036ceb8470abac09cdba894d2dd,
title = "Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs",
keywords = "cholesterol, clinical trial",
author = "Virani, \{Salim S.\} and Akeroyd, \{Julia M.\} and Vijay Nambi and Michos, \{Erin D.\} and Morris, \{Pamela B.\} and Khurram Nasir and Smith, \{Sidney C.\} and Stone, \{Neil J.\} and Petersen, \{Laura A.\} and Ballantyne, \{Christie M.\}",
note = "Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research \& Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1- 14-CE-44), and a Houston VA Health Services Research \& Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine. Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research \& Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and a Houston VA Health Services Research \& Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.",
year = "2019",
month = jan,
day = "15",
doi = "10.1161/CIRCULATIONAHA.118.034993",
language = "English (US)",
volume = "139",
pages = "410--412",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "3",
}